Emergent Biosolutions EPS - Earnings per Share 2010-2022 | EBS

Emergent Biosolutions eps - earnings per share from 2010 to 2022. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
Emergent Biosolutions Annual EPS
2021 $4.27
2020 $5.67
2019 $1.04
2018 $1.22
2017 $1.71
2016 $1.13
2015 $1.41
2014 $0.88
2013 $0.85
2012 $0.65
2011 $0.64
2010 $1.59
2009 $0.99
Emergent Biosolutions Quarterly EPS
2022-03-31 $-0.07
2021-12-31 $3.51
2021-09-30 $-0.61
2021-06-30 $0.09
2021-03-31 $1.28
2020-12-31 $3.45
2020-09-30 $0.73
2020-06-30 $1.73
2020-03-31 $-0.24
2019-12-31 $0.90
2019-09-30 $0.83
2019-06-30 $-0.18
2019-03-31 $-0.51
2018-12-31 $-0.07
2018-09-30 $0.41
2018-06-30 $0.98
2018-03-31 $-0.10
2017-12-31 $0.69
2017-09-30 $0.68
2017-06-30 $0.11
2017-03-31 $0.23
2016-12-31 $0.85
2016-09-30 $0.45
2016-06-30 $-0.27
2016-03-31 $0.10
2015-12-31 $0.87
2015-09-30 $0.79
2015-06-30 $0.32
2015-03-31 $-0.57
2014-12-31 $0.81
2014-09-30 $0.49
2014-06-30 $0.13
2014-03-31 $-0.55
2013-12-31 $0.42
2013-09-30 $0.36
2013-06-30 $0.29
2013-03-31 $-0.22
2012-12-31 $0.45
2012-09-30 $0.18
2012-06-30 $0.21
2012-03-31 $-0.19
2011-12-31 $0.82
2011-09-30 $0.04
2011-06-30 $0.39
2011-03-31 $-0.61
2010-12-31 $0.79
2010-09-30 $0.41
2010-06-30 $0.31
2010-03-31 $0.08
2009-12-31 $0.13
2009-09-30 $0.03
2009-06-30 $0.48
2009-03-31 $0.35
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.444B $1.793B
Emergent BioSolutions Inc. is strongly committed to the highest standards of ethical conduct and corporate governance. These standards are consistent with their corporate culture. The company understands that adhering to sound principles of corporate governance is critical to earning and maintaining the trust of their customers, employees and shareholders. The foundation of the corporate governance principles and practices are built on their reputation for openness, integrity and accountability. These are the principles that guide Emergent BioSolutions everyday. They have in place policies and practices to ensure that their Company is managed with integrity and in their shareholders' best interests. In addition, they are committed to meeting the requirements of federal and state law and the rules of the New York Stock Exchange.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $161.383B 9.82
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.475B 16.53
Biohaven Pharmaceutical Holding (BHVN) United States $9.944B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.681B 0.00
Arcus Biosciences (RCUS) United States $1.389B 35.22
Myovant Sciences (MYOV) United Kingdom $0.879B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.509B 0.00
Gelesis Holdings (GLS) United States $0.362B 0.00
Zymeworks (ZYME) Canada $0.321B 0.00
Ambrx Biopharma (AMAM) United States $0.159B 0.00
Enzo Biochem (ENZ) United States $0.114B 23.50
SQZ Biotechnologies (SQZ) United States $0.093B 0.00